Worldwide

Welcome to Pharma Group one of the worlds leading online pharmaceutical company with experience of supplying the very highest quality products from the worlds leading companies to clients in over twenty countries.



Taj Drug Menu | Taj Generics | Generics Index A - Z | Pharmalogical Index | New Drugs | Top Generics (200) | API & Chemicals
Vaccines & Injections | Export & Import | Countries | Brands | Home

bullets_red
Mauritania
bullets_red
Mauritius
bullets_red
Morocco
bullets_red
Mozambique
bullets_red
Namibia
bullets_red
Niger
bullets_red
Nigeria
bullets_red
Republic-of-Congo
bullets_red
Rwanda
bullets_red
Sao-tome-and-Principe
bullets_red
Senegal
bullets_red
Seychelles
bullets_red
Sierra-Leone
bullets_red
Somalia
bullets_red
South-Africa
bullets_red
Sudan
bullets_red
Swaziland
bullets_red
Tanzania
bullets_red
The-Gambia
bullets_red
Togo
bullets_red
Tunisia
bullets_red
Uganda
bullets_red
Australia
bullets_red
Palau
bullets_red
Brunei
bullets_red
Papua-guinea
bullets_red
Burma
bullets_red
Samoa
bullets_red
Cambodia
bullets_red
Singapore
bullets_red
China
bullets_red
Solomon-islands
bullets_red
East-timor
bullets_red
South-korea
bullets_red
Fiji
bullets_red
Taiwan
bullets_red
Indonesia
bullets_red
Tajikistan
bullets_red
Japan
bullets_red
Thailand
bullets_red
Kazakhstan
bullets_red
The-Philippines
bullets_red
Kiribati
bullets_red
Tonga
bullets_red
Kyrgyzstan
bullets_red
Turkmenistan
bullets_red
Laos bullets_red Tuvalu
bullets_red
Malaysia bullets_red Uzbekistan
bullets_red
Marshall-islands bullets_red Vanuatu
bullets_red
Micronesia bullets_red Vietnam
bullets_red
Mongolia    
bullets_red
Nauru    
bullets_red
New-zealand    
bullets_red
North-korea    
bullets_red
Antigua & Barbuda
bullets_red
Guyana
bullets_red
Bahamas
bullets_red
Grenada
bullets_red
Barbados
bullets_red
Haiti
bullets_red
Belize
bullets_red
Honduras
bullets_red
Bolivia
bullets_red
Jamaica
bullets_red
Brazil
bullets_red
Mexico
bullets_red
Canada
bullets_red
Nicaragua
bullets_red
Chile
bullets_red
St-lucia
bullets_red
Costa-rica
bullets_red
Suriname
bullets_red
Cuba
bullets_red
St-kitts-and-nevis
bullets_red
Colombia
bullets_red
Trinidad-and-tobago
bullets_red
Dominica
bullets_red
Uruguay
bullets_red
Dominican-republic bullets_red Venezuela
bullets_red
Ecuador
bullets_red
El-salvador
bullets_red
Guatemala    
Europe europe flag
bullets_red Albania bullets_red Liechtenstein
bullets_red Andorra bullets_red Lithuania
bullets_red Armenia bullets_red Luxembourg
bullets_red Austria bullets_red Macedonia
bullets_red Azerbaijan bullets_red Malta
bullets_red Belarus bullets_red Moldova
bullets_red Belgium bullets_red Monaco
bullets_red Bosnia-hercegovina bullets_red Montenegro
bullets_red Bulgaria bullets_red Norway
Middle East
bullets_red Algeria bullets_red Mauritania
bullets_red Egypt bullets_red Oman
bullets_red Iran bullets_red Qatar
bullets_red Iraq bullets_red Saudi-arabia
bullets_red Israel-&-palestinian bullets_red Sudan
bullets_red Jordan bullets_red Syria
bullets_red Kuwait bullets_red Tunisia
bullets_red Lebanon bullets_red United-arab-emirates
bullets_red Libya bullets_red Yemen
South Asia
bullets_red Afghanistan
bullets_red Bangladesh
bullets_red Bhutan
bullets_red India
bullets_red Nepal
bullets_red Pakistan
bullets_red Sri-Lanka
bullets_red The-Maldives
bullets_red Croatia bullets_red Poland
bullets_red Cyprus bullets_red Portugal
bullets_red Czech-republic bullets_red Russia
bullets_red Denmark bullets_red San-marino
bullets_red Estonia bullets_red Serbia
bullets_red Finland bullets_red Slovakia
bullets_red France bullets_red Slovenia
bullets_red Georgia bullets_red Spain
bullets_red Germany bullets_red Sweden
bullets_red Greece  
bullets_red Hungary  
bullets_red Iceland  
bullets_red Ireland  
bullets_red Italy  
bullets_red Latvia  

 


Ensure Market Access for Innovative Medicines

In many countries market access to innovative medicines is often delayed or denied because of complex regulatory and reimbursement procedures. In practically all countries with price regulation, new medicines are not launched as long as reimbursement and pricing decisions are pending. There is a global trend that clinical guidelines and Health Technology Assessments (HTA) produced by health authorities or payers are often used as a mechanism to restrict access of patients to innovative medicines.

 

** Science for a better life - Medical Progress for the Benefit of the Patient